Latest From ImmuPharma PLC
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.
US speciality drugs group will fund the $25m costs of the UK company's new Phase III trial of Lupuzor, which has been much maligned by analysts.
The UK biotech is expanding access to its unapproved lupus drug, has signed a licensing deal with Incantera and unveiled plans to divest its metabolic disorder subsidiary Ureka but fears about ImmuPharma's future remain.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- ImmuPharma PLC
- Senior Management
Dimitri F Dimitriou, CEO
Tracy Weimar, VP, Fin. & Operations
Robert Zimmer, MD, PhD, Pres. & CSO
- Contact Info
Phone: (44) 20 7152 4080
London, SW1H 0RG
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.